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ABSTRACT Acetyl-CoA carboxylase, which has a molec-
ular mass of265 kDa (ACC-c), catalyzes the rate-limiting step
in the biosynthesis of long-chain fatty acids. In this study we
report the complete amino acid sequence and unique features
of an isoform of ACC with a molecular mass of 275 kDa
(ACC-,B), which is primarily expressed in heart and skeletal
muscles. In these tissues, ACC-18 may be involved in the
regulation of fatty acid oxidation, rather than fatty acid
biosynthesis. ACC-.3 contains an amino acid sequence at the
N terminus which is about 200 amino acids long and may be
uniquely related to the role of ACC-f8 in controlling carnitine
palmitoyltransferase I activity and fatty acid oxidation by
mitochondria. If we exclude this unique sequence at the N
terminus the two forms of ACC show about 75% amino acid
identity. All of the known functional domains of ACC are
found in the homologous regions. Human ACC-. cDNA has an
open reading frame of 7,343 bases, encoding a protein of 2,458
amino acids, with a calculated molecular mass of 276,638 Da.
The mRNA size of human ACC-,f is approximately 10 kb and
is primarily expressed in heart and skeletal muscle tissues,
whereas ACC-a mRNA is detected in all tissues tested. A
fragment of ACC-f8 cDNA was expressed in Escherichia coli
and antibodies against the peptide were generated to establish
that the cDNA sequence that we cloned is that for ACC-38.
The primary species of mammalian acetyl-CoA carboxylase
(ACC) expressed in lipogenic tissues has a molecular mass of
265 kDa (ACC-a)§ (1, 2). ACC-a catalyzes the rate-limiting
reaction in the biogenesis of long-chain fatty acids; the reaction
product, malonyl-CoA, which is generated only by ACC, is the
substrate for fatty acid synthesis. In contrast, although non-
lipogenic tissues, such as skeletal and cardiac muscle, in which
fatty acids serve as the primary source of energy, contain trace
amounts of ACC-a, their predominate form of ACC has a
molecular mass of 275-280 kDa (ACC-,B) (3-5). In muscle
tissue, ACC-f3 is thought to control fatty acid oxidation by
means of the ability of malonyl-CoA to inhibit carnitine-
palmitoyl-CoA transferase I (CPT-I), the rate-limiting step in
fatty acid uptake and oxidation by mitochondria (3, 6, 7).
Because of the lack of knowledge about the molecular
features of ACC-f3, the regulatory mechanisms by which fatty
acid oxidation in mitochondria is regulated by ACC and
malonyl-CoA are largely unknown. Derangements in mito-
chondrial fatty acid oxidation lead to various diseases, includ-
ing sudden infant death syndrome, cardiomyopathy, and vas-
cular myopathy (8-10). To explore the role that ACC-,B plays
in the control of CPT-I and fatty acid oxidation we have cloned
human ACC-,B cDNA.
ACC-3 (11), which is the product of a gene distinct from that
for ACC-a (12), has some unusual features, which may be
critical to its role in fatty acid oxidation.
MATERIALS AND METHODS
Materials. Human skeletal muscle cDNA library, human
skeletal muscle total RNA, and human multiple tissue North-
ern blot were purchased from CLONTECH. Taq DNA poly-
merase and restriction enzymes were purchased from Pro-
mega; all isotopes were purchased from Amersham. Cell
culture media, calf donor serum, and horse serum were
purchased from GIBCO/BRL. Streptavidin-alkaline phos-
phatase conjugate was from Sigma. pCRII T-vector was pur-
chased from Invitrogen. Dulbecco's modified Eagle's medi-
um/F-12 was from GIBCO/BRL.
Cloning ofHuman ACC Clones. The primers (19-mer) were
designed based on the human ACC-a sequence (13), synthe-
sized, and used to isolate human ACC-f3 clones by polymerase
chain reaction (PCR). DNA was purified from human skeletal
muscle cDNA library and was used as a template for PCR (1
,ug per reaction). The protocol for PCR was the same as
described in ref. 13, except for the annealing temperature
which varied from 45°C to 60°C, depending on the designed
primers. To isolate the initial clone by PCR, we designed one
primer (sense sequence) at the biotin-binding site of human
ACC-a in such a way that nucleotides encoding Met-Lys-Met
were located at the 3' end of the primer. Using this primer and
the other primer, which was designed on the basis of human
ACC-a, we were able to isolate the first clone, clone A (base
3037-5518). Clone A shows 70% identity in amino acid
sequence in comparison with human ACC-a. Similarly, using
one primer from clone A and the other from human ACC-a,
we isolated two additional clones, clone B (base 1108-3137)
and clone C (base 5439-7784), which overlap the 5' and 3' ends
of clone A, respectively. The final clone, D (base 1-1174),
which contains the first translation initiation codon, was
isolated by PCR using one primer from the 5' end of clone B
and another primer for the region of the cloning site of Agtl1.
PCR products were inserted into pCRII (Invitrogen) and
cloned.
Expression of ACC-,f Specific cDNA and Antibody Gener-
ation. For the construction of expression vector for the 215
amino acids at the N-terminal region of ACC-13 (from the
initiation methionine to threonine at 215), a 645-bp DNA
fragment containing the NdeI and XhoI sites was amplified
through PCR. The amplified PCR products were digested with
NdeI and XhoI and inserted into the plasmid pET-22b(+),
which had been digested with the same pair of restriction
enzymes. Escherichia coli BL21(DE3) was used to overexpress
the plasmids. The expressed protein was partially purified
using a His-Tag column (Novagen), and partially purified
protein was further purified on SDS/8% PAGE. The ex-
Abbreviations: ACC, acetyl-CoA carboxylase; CPT-I, carnitine-
palmitoyl-CoA transferase I.
STo whom reprint requests should be addressed.
§In this manuscript, we used the suggested terminology, ACC-ct and
ACC-,3, to avoid designation of these polypeptides by molecular size,
as discussed in ref 11.
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pressed ACC-fB peptide band was excised and used to generate
antibodies in rabbits.
Miscellaneous Procedures. Northern blot analysis (15),
Western blot analysis (16), and nick translation (15) were
performed as described.
RESULTS
Isolation of Human ACC-,f cDNA Clones. Because ACC-,B
is primarily expressed in muscle tissues, we used DNA purified
from human skeletal muscle cDNA library as the template for
our PCR reactions in our search for the cDNA coding for
ACC-,B. We have isolated four clones, as discussed in Materials
and Methods, whose sequences overlapped to give an 8-kb long
cDNA sequence with an open reading frame of 7343 bases,
encoding a protein of 2458 amino acids (Fig. 1). The calculated
molecular weight is 276,638 Da. All of the clones hybridized
with a skeletal muscle RNA species about 10 kb long (Fig. 2).
The major molecular difference between human ACC-a and
ACC-f3 is that the first 217 amino acids of ACC-,B include
practically no amino acid homology or identity with the first 74
amino acids ofACC-a (13), whereas the remaining amino acid
sequences show about 75% identity. Thus, a sequence of about
200 amino acids is unique to ACC-f3, and this portion of
ACC-,B may be involved in functions specific to ACC-,3. This
aspect is discussed further in the Discussion. The molecular
weight difference between the two species is largely due to the
presence of the extra sequence at the N terminus of ACC-/3.
Once ACC-a and the ACC-,B species are aligned, based on
amino acid identity, the functional sites of both species are
spaced at approximately the same distances. These functional
sites (Fig. 1) include the biotin binding site, the acyl-CoA
binding site, the ATP binding site, as well as the enzyme
inactivating phosphorylation sites at Ser-79 and Ser-1200
(ACC-a), which are the substrates for 5'-AMP-dependent
protein kinase and cAMP-dependent protein kinase, respec-
tively (16). In the case of ACC-,, the Ser-1200 of ACC-a is
represented by a threonine residue. It is known that 5'-AMP-
dependent protein kinase is more abundant in heart and
muscle than in other tissues (17-19), and 5'-AMP-dependent
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FIG. 1. Complete deduced amino acid sequence from cDNA of human ACC-,B. Mito-sequence (the ACC-,3 specific N-terminal sequence),
boldface type and underlined; the site phosphorylated on ACC-a by 5'-AMP-dependent protein kinase, shaded box; the ATP binding region, open
box region; the biotin binding site, underlined; the site phosphorylated on ACC-a by cAMP-dependent protein kinase, filled box; the acyl-CoA
binding region, double underline.
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FIG. 2. Northern blot analysis of human ACC mRNA using the
individual cDNA clones. Each lane contains 30 jig of human skeletal
muscle total RNA and each blot was separately hybridized with the
following cDNA as a probe. Lane 1, clone A; lane 2, clone B; lane 3,
clone C; lane 4, clone D.
protein kinase may be primarily responsible for phosphoryla-
tion and inactivation ofACC-f3 in vivo (20). Numerous possible
phosphorylation sites, including those recognized by the
cAMP-dependent protein kinase, protein kinase C, and casein
kinase II, are found in the N-terminal 200-amino acid se-
quence of ACC-,B. The possible regulatory consequences of
phosphorylation in the N-terminal region of ACC-f3 are dis-
cussed in detail in the Discussion.
Expression Pattern of Human ACC-18 mRNA in Various
Human Tissues. The relative levels of expression of the two
species of ACC are tissue specific. For example, ACC-,B is the
predominant species in heart and skeletal muscle tissues, which
have only a small amount of ACC-a (3, 4, 11). The reverse is
true in the case of lipogenic tissues such as liver and fat tissues.
These tissue-specific expression pattems are reflected in the
abundance of the corresponding mRNA species (Fig. 3). As
shown in Fig. 3A, the probe specific for ACC-f3 hybridized
strongly only with 10 kb mRNA from heart and muscle tissue,
whereas practically no signals were detected in the samples
from liver, pancreas, and kidney at this concentration of total
RNA. On the other hand, mRNA species for ACC-a were
detected in all samples of tissue tested (Fig. 3B). Previously, we
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FiG. 4. Western blot analysis of ACC in various cells. Ten micro-
grams of total protein from different cells were used for Western blot
analysis. Streptavidin-alkaline phosphatase obtained from Sigma was
used for Western blot analysis (15). Lanes: 1, 30A5 preadipocytes; 2,
HepG2; 3, INS-1 ,B cells; 4, H9c2 cardiomyoblasts; 5-8, H9c2 cells were
induced to differentiate (11) for 2, 4, 5, and 6 days, respectively.
indicated that white adipose tissues showed very little ACC-P3
mRNA, if any (11). The expression patterns of ACC-a and
ACC-,B in different cell lines are shown in Fig. 4. Lanes 1-4
show that 30A5 preadipocytes (lane 1), HepG2 (lane 2), INS-1
pancreatic 13-cell line (lane 3), and H9c2 cardiomyoblasts (lane
4) express only appreciable amounts of ACC-a, but not
ACC-3, as examined under these experimental conditions.
However, ACC-,B was selectively induced when the H9c2 cells
were induced to differentiate into myocytes (11). These results,
together with the expression of ACC-a and ACC-,3 in skeletal
and heart muscle tissues shown in Fig. 5, indicate that the
relative expression patterns of the two species ofACC is tissue
specific.
To unequivocally establish that the cDNA that we have
cloned is that of ACC-f3, we expressed the 215-amino acid
peptide at the N terminus, which is specific to ACC-f3, and
generated antibodies against the peptide. As shown in Fig. 5,
the antibodies removed the ACC-,B species specifically from
the homogenates of mouse skeletal muscle and differentiating
muscle cells. Homogenate from mouse skeletal muscle shows
primarily the 1-form ofACC and a small amount of the a-form
(Fig. SA, lane 1). Different antibody preparations removed
ACC-f specifically, without' affecting the amount of the
a-form (Fig. SA, lanes 2-5). In Fig. SA, lane 5, the make-up of
ACC in rat H9c2 embryonic cardiomyocytes following 4 days
of differentiation is shown. ACC-,B was completely removed
2 3 4 5
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B
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FIG. 3. Expression of human ACC mRNA in various human
tissues. Northern blot analysis was performed using the multiple
human tissue blot from CLONTECH. (A) The blot was hybridized
with an ACC-13 specific probe. For this experiment, we first generated
probes that were specific to each mRNA species. cDNA fragments of
'600 nucleotides, including the region from amino acids 1338-1470 of
ACC-13, as well as the corresponding cDNA fragment of ACC-a, were
generated by PCR. (B) The same blot was stripped of radioactivity and
rehybridized with ACC-a specific probe. Lanes: 1, heart; 2, brain; 3,
placenta; 4, lung; 5, liver; 6, skeletal muscle; 7, kidney; 8, pancreas.
Each lane contains 2 ,ug of poly(A) mRNA.
FIG. 5. Effect of antiserum to the mito-sequence on ACC-,B
immunoprecipitation. (A) Mouse skeletal muscle homogenates were
treated with different antisera (2 ,lI) bound to protein A-Sepharose
CL-4B (25 ,ul) as described (21). Following the removal of the
precipitates by centrifugation, the supernatants were analyzed by
Western blot analysis using streptavidin-alkaline phosphatase conju-
gates. Lane 1, homogenates that had been treated with control serum;
lanes 2 and 3, homogenates treated with antiserum (2 ,ul) from two
different rabbits. H9c2 cells were induced to differentiate for 4 days as
described (11). Homogenates were prepared and treated with protein
A-Sepharose CL-4B, which had been treated with the control serum
(lane 5) or with the antiserum (lane 4). Following centrifugation, the
supernatants were examined by Western blot analysis as described
above. (B) Rat heart homogenates were used for Western blot analysis
(15). Lane 1 was probed with streptavidin-alkaline phosphatase. The
lane 2 filter was split into two parts and the left half was probed with
streptavidin-alkaline phosphatase and the right half with anti-ACC-,B.
Lane 3 was probed with anti-ACC-,B.
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when the homogenate of differentiated muscle cells was
analyzed following the treatment with the antibodies against
ACC-13. As shown in Fig.5B, where a Western blot analysis was
carried out, our antibodies also crossreacted specifically with
the ACC-,3 in the homogenates of rat heart (Fig.SB, lane 2).
When antibodies against streptavidin were used, both ACC-a
and ACC-13 were identified (Fig.SB, left half of lane 2 and lane
1), whereas our antibodies only identified ACC-,B (Fig.SB,
right half of lane 2 and lane 3). Because antibodies were
generated by the peptide whose coding sequence was based on
the cloned cDNA, this result established that the cDNA
sequence is for ACC-,3.
DISCUSSION
The general belief that ACC plays a role in the control of fatty
acid oxidation was based on the following observations. First,
CPT-I, an essential component of fatty acid oxidation, is
extremely sensitive to malonyl-CoA inhibition (6, 7,22,23) and
malonyl-CoA is only generated by ACC. Second, muscle
tissues are non-lipogenic and yet contain a large amount of
ACC. Recently, the ACC in these tissues was found to be
mostly the ACC form with a molecular mass of 275-280 kDa
(3, 24, 25). Physiological conditions that cause a decrease in
ACC activity and malonyl-CoA levels are accompanied by
accelerated rates of fatty acid oxidation in liver (26) and heart
(20, 24, 27).
CPT-I, which is located in the inner phase of the outer
membrane of the mitochondrion (28), catalyzes the rate-
limiting step in fatty acid uptake and fatty acid oxidation.
McGarry et al. (7), and other groups, established that CPT-I
is particularly sensitive to malonyl-CoA inhibition (7). It is
obvious that the mechanism by which the concentration of
malonyl-CoA near the malonyl-CoA binding component of
CPT-I is controlled must be a vital aspect of the regulation of
fatty acid oxidation. The malonyl-CoA binding component of
CPT-I faces the outer phase (the cytosolic sphere) of the outer
membrane of the mitochondrion (28), whereas the catalytic
region of CPT-I faces the inner phase of the outer membrane
(28). Thus, ACC-,B would not have to be imported into the
inner phase to control CPT-I activity.
The N-terminal sequence of about 200 amino acids unique
to ACC-f3 is rich in hydroxy amino acids (46 serines and
threonines) and basic amino acids (25 arginines and lysines).
Such an amino acid composition is typical of transit peptides
that target to mitochondria and chloroplasts (29). However,
this sequence is frequently broken by proline residues (17
prolines between residues 31 and 147). Although there are
abundant basic amino acids, they are counterbalanced by a
comparable number of acidic residues (23 glutamic and as-
partic acids). Not only is the whole sequence comparatively
long, but the above features would make it difficult to form the
amphiphilical secondary structures that are found in the
mitochondrial import proteins. Overall, the unique sequence
exhibits strong hydrophilic features, except for the first 25-
amino acid portion of the N terminus, which contains a
hydrophobic region surrounded by positive charges, a typical
feature of mitochondrial signal peptides. However, this region
does not form the ideal amphiphilical secondary structure that
is required for mitochondrial import proteins.
Our hypothesis is that this region of ACC-,B may be required
for targeting and/or anchoring to the mitochondrial outer
membrane in such a way as to control the malonyl-CoA
regulatory site of CPT-I, which faces the cytosolic side of the
outer membrane of the mitochondrion (28). This hypothesis is
illustrated in Fig. 6. In this diagram the ACC-f3-specific N
terminal sequence is designated as the mito-sequence. The
hydrophobic region of ACC-, (the first 25 amino acids) may
be responsible for binding or anchoring into the outer mem-
brane of the mitochondrion. This could control CPT-I activity
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FIG. 6. Role of ACC-,B in the control of CPT-I. In this model, the
N-terminal hydrophobic region of the mito-sequence is responsible for
anchoring or binding of ACC-f3 in such a way as to control malonyl-CoA concentration near the malonyl-CoA binding site of CPT-I.
Phosphorylation/dephosphorylation of the hydroxy amino acid resi-dues in the mito-sequence may control the binding or anchoring ofACC-, to the outer membrane of the mitochondrion.
by generating malonyl-CoA at or near the malonyl-CoA bind-ing site of CPT-I. Our second hypothesis concerning this
model is that the phosphorylation of the mito-sequence at
serine and threonine residues could control ACC-,3 binding or
anchoring to the membrane by increasing negative charges on
the mito-sequence. In the absence of phosphorylation, thebasic amino acids on the mito-sequence would interact with the
negative charges of the membrane lipids and augment thehydrophobic interaction between the hydrophobic region ofACC-, and the outer membrane. This model is currently being
experimentally tested. Such interactions could increase thelocal concentration of a metabolite as much as 1000-fold (30).
Allred and coworkers have reported that some species of
ACC do bind to the outer membrane of liver mitochondria
reversibly, as much as 75%, depending upon the physiological
condition of the rats (31, 32). However, the association ofACC-, with mitochondria has not been easily demonstrated(33, 34). It is possible that proteolytic cleavage of the N-
terminal segment might occur during subcellular fractionation,
releasing the catalytic domain of ACC-,B to the cytosol.
mRNAs for the two forms of ACC occur in all tissues that
we have examined, although their relative amounts are tissue
specific. In addition, these two enzymes catalyze the same
reaction. mRNAs of both forms of ACC are about 10 kbp long
and the cloning and sorting of cDNA fragments have been
extremely difficult. We have previously reported a cDNA
sequence for human ACC-a, which is a hybrid molecule of the
ACC-a and ACC-13 forms (13). A recent report of a different
version of the human ACC sequence (14) prompted us to
reexamine the alignment of different ACC clones and to
perform additional cloning to clarify the nature of the human
ACC cDNA clones. It is clear that the human cDNA sequence
reported by Abu et al. (14) is that of ACC-a. Those clonesisolated from the cDNA library, which was constructed using
the total RNA of human white adipose tissue (13), contained
the sequences for ACC-13, whereas the sequences obtained by
PCR using HepG2 RNA represented those of ACC-a. Al-
though the white adipose tissue or 3OA5 preadipocytes show nodetectable amounts of ACC-f3 mRNA or protein, the cDNA
library, which was constructed using the white adipose tissue,
contained readily detectable cDNA clones (13). However,
these clones were restricted to those representing about a 3-kb
i.- 11" ..
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long fragment for the 3'-end (11, 13). These observations
indicate that ACC-,B is expressed in all cells including adipose
tissues. If ACC-f3 is indeed involved in the control of mito-
chondrial fatty acid oxidation, it is reasonable to expect that
ACC-13 is expressed in all cells.
The sequence reported here is for ACC-,3. Its gene has been
localized to chromosome 12 (11), whereas the ACC-a gene is
on chromosome 17 (12).
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